Myriad Genetics, Inc.
) reported results from a crucial clinical validation study of its
myPath Melanoma test at the 2014 American Society of Clinical
Oncology (ASCO) annual meeting in Chicago.
The Myriad myPath Melanoma test is a clinically validated gene
expression molecular test that has been designed to differentiate
malignant melanoma from benign skin lesions, with a high level of
With certain melanomas imitating benign skin lesions, it becomes
quite difficult for clinicians to diagnose melanoma in patients
accurately. In such situations, Myriad myPath Melanoma comes of
help as it has the ability to discriminate malignant melanoma from
benign skin lesions, as has been observed in the validation study.
The test differentiates between the two diseases by using
traditional dermatopathology as a gold standard. A quick and
accurate diagnosis of potentially fatal melanoma is now possible,
thanks to Myriad myPath Melanoma.
The validation study evaluated 437 pigmented lesions
representing a wide variety of subtypes submitted from 4 academic
medical centers in the U.S. In the study, the Myriad myPath
Melanoma test effectively discriminated malignant melanoma from
benign skin lesions with 90% sensitivity and 91% specificity.
The current study findings follow Myriad's data from the earlier
verification study of 464 lesions. Results back then had revealed
that Myriad myPath Melanoma showed diagnostic accuracy of more than
90% in differentiating malignant melanoma from benign skin lesions
in a variety of subtypes.
Management at Myriad strongly believes that myPath Melanoma has
the potential to significantly improve the standard of patient care
for those diagnosed with melanoma. With this test, it will be much
easier for physicians to detect whether a patient has malignant
melanoma that needs surgical or medical intervention or whether it
is just a case of harmless skin lesion. Accordingly, appropriate
therapy can be administered to the patient.
Moreover, an analysis of a potential clinical utility study was
also featured at ASCO. The initial findings from this study are
found to be consistent with earlier data from a retrospective
clinical utility study that was presented at the United States
& Canadian Academy of Pathology's (USCAP) annual meeting in
March this year. The USCAP data validated a 33% change in medical
management based upon the Myriad myPath Melanoma test results.
Myriad currently has a Zacks Rank #2 (Buy).
Other well-placed Bio-medical stocks that warrant a look include
ANI Pharmaceuticals, Inc.
Gilead Sciences Inc.
). All these stocks carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ILLUMINA INC (ILMN): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis
MYRIAD GENETICS (MYGN): Free Stock Analysis
ANI PHARMACEUT (ANIP): Free Stock Analysis
To read this article on Zacks.com click here.